首页> 外文期刊>Cancer research: The official organ of the American Association for Cancer Research, Inc >Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer.
【24h】

Regulated expression of a tumor-associated antigen reveals multiple levels of T-cell tolerance in a mouse model of lung cancer.

机译:肿瘤相关抗原的调控表达揭示了肺癌小鼠模型中T细胞耐受性的多个水平。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Maximizing the potential of cancer immunotherapy requires model systems that closely recapitulate human disease to study T-cell responses to tumor antigens and to test immunotherapeutic strategies. We have created a new system that is compatible with Cre-LoxP-regulatable mouse cancer models in which the SIY antigen is specifically overexpressed in tumors, mimicking clinically relevant TAAs. To show the utility of this system, we have characterized SIY-reactive T cells in the context of lung adenocarcinoma, revealing multiple levels of antigen-specific T-cell tolerance that serve to limit an effective antitumor response. Thymic deletion reduced the number of SIY-reactive T cells present in the animals. When potentially self-reactive T cells in the periphery were activated, they were efficiently eliminated. Inhibition of apoptosis resulted in more persistent self-reactive T cells, but these cells became anergic to antigen stimulation. Finally, in the presence of tumors overexpressing SIY, SIY-specific T cells required a higher level of costimulation to achieve functional activation. This system represents a valuable tool in which to explore sources contributing to T-cell tolerance of cancer and to test therapies aimed at overcoming this tolerance.
机译:要最大程度地发挥癌症免疫疗法的潜力,就需要能够紧密概括人类疾病的模型系统,以研究T细胞对肿瘤抗原的反应并测试免疫治疗策略。我们创建了一个与Cre-LoxP调控的小鼠癌症模型兼容的新系统,其中SIY抗原在肿瘤中特异性过表达,模仿了临床​​相关的TAA。为了显示该系统的实用性,我们在肺腺癌的背景下表征了SIY反应性T细胞,揭示了多种水平的抗原特异性T细胞耐受性,这些水平可用来限制有效的抗肿瘤反应。胸腺缺失可减少动物体内SIY反应性T细胞的数量。当外围潜在的自我反应性T细胞被激活时,它们被有效地消除了。凋亡的抑制导致更持久的自我反应性T细胞,但这些细胞对抗原刺激无反应。最后,在过度表达SIY的肿瘤的存在下,SIY特异性T细胞需要更高水平的共刺激来实现功能激活。该系统代表了一种有价值的工具,可在其中探索有助于癌症T细胞耐受性的来源并测试旨在克服这种耐受性的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号